175865-60-8

Antiviral.

ChEBI: The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.

Valganciclovir (Valcyte) is the L-valyl ester prodrug of ganciclovir.

Valcyte (Roche).

Oral valganciclovir is comparable to intravenous ganciclovir for the treatment and suppression of CMV retinitis in AIDS patients.

Potentially hazardous interactions with other drugs
Antibacterials: increased risk of convulsions with imipenem-cilastatin.
Antivirals: possibly increased didanosine concentration; profound myelosuppression with zidovudine - avoid if possible.
Mycophenolate: possibly increased concentrations of both mycophenolic acid and ganciclovir.
Increased risk of myelosuppression with other myelosuppressive drugs.

Valganciclovir is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Valganciclovir is eliminated in the urine as unchanged ganciclovir, mainly by glomerular filtration and also active tubular secretion.

Store at -20°C